Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
About
This Notice of Funding Opportunity (NOFO) solicits applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO is focused on early-stage development from prototyping to initial dissemination. Early-stage development is defined for the purpose of this NOFO as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale for why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from driving research projects and other users throughout the development process must be included. This NOFO encourages applications that involve the development of new, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research. The emphasis is on uniqueness an.
The Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) grant is designed for researchers, technology developers, and innovators working to create cutting-edge informatics solutions that advance cancer research and patient care. This National Cancer Institute (NCI) funding opportunity supports the development of enabling technologies that improve how cancer research data is acquired, managed, analyzed, and shared across the entire cancer research continuum—from basic biology and early detection to treatment, diagnosis, risk assessment, and cancer control. This grant is ideal for teams with promising prototypes or significantly modified existing tools ready for initial development and dissemination. Applicants should demonstrate clear rationale for why their proposed technology is needed and how it will benefit the cancer research field. The program emphasizes user-friendly, innovative solutions that support diverse research areas including discovery biology, population studies, clinical research, and translational science. Successful applicants must include mechanisms for gathering feedback from research projects and end-users throughout development. If you're developing informatics tools that could transform cancer research accessibility and efficiency, this grant provides the funding and support to move your technology from concept toward real-world implementation.
Funding Facts
● Applications openDeadline
October 19, 2027
Award Amount
$50K - $300K
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Grant Amount
$50K - $300K
Deadline
2027-10-19
Grant Type
federal
Application Cycle
Annual (Deadline: October 19, 2027)
Best For
Researchers, institutions, and organizations developing informatics technologies for cancer research; academic institutions; research centers; technology development teams; international collaborators
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Frequently Asked Questions
Who is eligible for Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)?
Eligible applicants include domestic and non-domestic (non-U.S.) entities, foreign organizations, and non-domestic components of U.S. organizations. Foreign components are also allowed. For complete eligibility requirements including institutional qualifications, organizational requirements, and specific researcher credentials, refer to Section III of the official Notice of Funding Opportunity (NOFO) on the NIH website.
How much funding does Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) provide?
Funding ranges from $50,000 to $300,000. The specific amount awarded depends on your project scope, development timeline, and budget justification. Consult the official NOFO for current funding levels and any updates for specific funding cycles.
How do I apply for Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)?
Applications are submitted through the NIH grants submission system (Grants.gov). You will need to prepare a detailed proposal outlining your informatics technology, its rationale, development timeline, user feedback mechanisms, and expected impact on cancer research. The application deadline is October 19, 2027. Visit the official NCI ITCR Program website and the NIH NOFO page for complete application instructions, required forms, and submission guidelines.
What can Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) funding be used for?
Funding supports early-stage development of informatics technologies, including initial tool development and significant modification of existing tools for new cancer research applications. Supported activities include tool development, prototyping, implementation, user engagement and feedback mechanisms, documentation, testing, and initial dissemination of informatics solutions that improve data acquisition, management, analysis, or dissemination across cancer research areas such as discovery biology, population studies, clinical research, treatment, diagnosis, early detection, and cancer control.
Last updated: July 5, 2026